ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test

ALZpath signed a global licensing agreement with Abbott Laboratories to advance blood-based testing for Alzheimer's disease. The deal supports development of easier-to-use diagnostic options in a large and growing healthcare market. The news is positive for both companies but is likely to have limited immediate market impact absent financial terms or regulatory milestones.

Analysis

ALZpath signed a global licensing agreement with Abbott Laboratories to advance blood-based testing for Alzheimer's disease. The deal supports development of easier-to-use diagnostic options in a large and growing healthcare market. The news is positive for both companies but is likely to have limited immediate market impact absent financial terms or regulatory milestones.